[Docetaxel as salvage treatment for non-small cell lung cancer: implementation study].
Fiche publication
Journal
Revue medicale de Bruxelles
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Mascaux C, Iannino N, Berghmans T, Meert AP, Sculier JP
Lien Pubmed
Résumé
Salvage treatment with docetaxel after failure of cisplatin-based chemotherapy in non-small cell lung cancer (NSCLC) has already been tested in the context of clinical prospective trials but only dealing with selected patients. The aim of the present study is to assess the generalizability of these results in an unselected population. We retrospectively analysed the data of all patients not included in clinical studies and treated at the Jules Bordet Institute between September 1996 and July 2003 by docetaxel after a previous chemotherapy containing platinum. Patients were separated in two groups: eligible or not studies according to the selection criteria of the published phase II and III prospective trials. There were 27 patients treated by docetaxel after relapse or failure of prior first-line platinum-based chemotherapy. Among them, 15 were ineligible according to the criteria of published phase II and III trials. The global response rate was 7.41%. All responders had a partial response to first line chemotherapy. Toxicity consisted mainly in grade III/IV neutropenia and was similar between the two group of patients. The median survival time was 25 weeks. In conclusion, our implementation study confirms the activity of docetaxel as salvage therapy after failure of first line cisplatin-based chemotherapy in an unselected population of patients with NSCLC, with a response rate similar to that obtained in propective trials.
Mots clés
Adult, Aged, Antineoplastic Agents, Phytogenic, therapeutic use, Carcinoma, Non-Small-Cell Lung, drug therapy, Docetaxel, Female, Humans, Lung Neoplasms, drug therapy, Male, Middle Aged, Retrospective Studies, Salvage Therapy, Taxoids, therapeutic use
Référence
Rev Med Brux. ;26(3):153-8